Monitoring of Serum Her-2/neu Predicts Histopathological Response to Neoadjuvant Trastuzumab-based Therapy for Breast Cancer

Anticancer Research

Volumn 24, Issue 2 C, 2004, Pages 1127-1130

  Köstler, Wolfgang J ^a   Steger, Günther G ^a   Soleiman, Afschin ^a   Schwab, Barbara ^a   Singer, Christian F ^a   Tomek, Sandra ^a   Brodowicz, Thomas ^a   Krainer, Michael ^a   Wiltschke, Christoph ^a   Horvat, Reinhard ^a   Jakesz, Raimund ^a   Zielinski, Christoph C ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Breast cancer; C erbB2; Extracellular domain; Trastuzumab

Indexed keywords

DOCETAXEL; EPIRUBICIN; NAVELBINE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEGRADATION; SERUM; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; MULTICENTER STUDIES; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; TAXOIDS; VINBLASTINE;

EID: 2442613063     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Valagussa P, Zambetti M, Bonadonna G, Zucali R, Mezzanotte G and Veronesi U: Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat 15: 137-47, 1990.
2. Jacquillat C, Weil M, Baillet F et al: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119-29, 1990.
3. Schwartz GF, Birchansky CA, Komarnicky LT et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73: 362-9, 1994.
4. Kuerer HM, Newman LA, Smith TL et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-9, 1999.
5. Fisher B, Bryant J, Wolmark N et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-85, 1998.
6. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC and Blumenschein GR: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46: 2578-81, 1986.
7. Maloisel F, Dufour P, Bergerat JP et al: Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 65: 851-5, 1990.
8. Fisher B, Brown A, Mamounas E et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-93, 1997.
9. Brain E, Garrino C, Misset JL et al: Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br J Cancer 75: 1360-7, 1997.
10. Huber S, Wagner M, Zuna I, Medl M, Czembirek H and Delorme S: Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy. Anticancer Res 20: 553-8, 2000.
11. Nunes RA, Burstein H, Gakhar M et al: Serum HER2 in breast cancer patients treated with preoperative therapy with herceptin and taxol (H&T). Proc Am Soc Clin Oncol 20: 34, 2001.
12. Hurley J, Doliny P, Silva O et al: Neoadjuvant herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol 22: 50, 2002
13. Steger GG, Wenzel C, Bartsch R, Rudas M, Gnant MF, Zielinski CC and Jakesz R: Preliminary results of a pilot-trial with trastuzumab + weekly epidoxorubicin/docetaxel in the neoadjuvant treatment of primary, operable breast cancer. Breast 12: S39-40, 2003.
14. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A and Jager W: Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 43: 87-95, 1997.
15. Isola JJ, Holli K, Oksa H, Teramoto Y and Kallioniemi OP: Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 73: 652-8, 1994.
16. Krainer M, Brodowicz T, Zeillinger R et al: Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 54: 475-81, 1997.
17. Narita T, Funahashi H, Satoh Y and Takagi H: C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 24: 97-102, 1993.
18. Kostler WJ, Schwab B, Singer C et al: Predictive value of serum Her-2/ neu extracellular domain (ECD) during trastuzumab-based therapy in patients with breast cancer. Proc Am Assoc Cancer Res 43: 490, 2002.
19. American Joint Committee on Cancer: Manual for Staging of Cancer. Philadelphia: J.B. Lippincott, 1998.
20. Burstein HJ, Kuter I, Campos SM et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722-30, 2001.
21. Green S and Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239-53, 1992.
22. de Matteis A, Nuzzo F, D'Aiuto G et al: Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 94: 895-901, 2002.
23. Chevallier B, Roche H, Olivier JP, Chollet P and Hurteloup P: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16: 223-8, 1993.
24. Lipton A, Ali SM, Leitzel K et al: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467-72, 2002.
25. Molina R, Jo J, Filella X et al: C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 16: 2295-300, 1996.
26. Molina R, Jo J, Filella X et al: c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 51: 109-19, 1998.
27. Cook GB, Neaman IE, Goldblatt JL et al: Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 21: 1465-70, 2001.